Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections.
Spero is advancing SPR994, which is designed to be the first broad-spectrum oral antibiotic for use in adults to treat MDR Gram-negative infections.
Spero is also advancing its Potentiator Platform, which it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. SPR741, Spero’s lead potentiator product candidate, is a clinical-stage IV-administered agent that has demonstrated in vitro an ability to potentiate over two dozen existing antibiotics by expanding their activity against Gram-negative pathogens.
Copyright Nasdaq. Minimum 15 minutes delayed.
- June 05, 2018 Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018
- June 01, 2018 Spero Therapeutics to Present at the Jefferies 2018 Healthcare Conference in June
- May 23, 2018 Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform